These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32567545)

  • 1. Efficacy and safety of biological agents in patients with giant cell arteritis: A meta-analysis of randomized trials.
    Song GG; Lee YH
    Int J Clin Pharmacol Ther; 2020 Sep; 58(9):504-510. PubMed ID: 32567545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological treatments in giant cell arteritis & Takayasu arteritis.
    Samson M; Espígol-Frigolé G; Terrades-García N; Prieto-González S; Corbera-Bellalta M; Alba-Rovira R; Hernández-Rodríguez J; Audia S; Bonnotte B; Cid MC
    Eur J Intern Med; 2018 Apr; 50():12-19. PubMed ID: 29146018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index.
    Berti A; Cornec D; Medina Inojosa JR; Matteson EL; Murad MH
    Semin Arthritis Rheum; 2018 Aug; 48(1):77-82. PubMed ID: 29496228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.
    Langford CA; Cuthbertson D; Ytterberg SR; Khalidi N; Monach PA; Carette S; Seo P; Moreland LW; Weisman M; Koening CL; Sreih AG; Spiera R; McAlear CA; Warrington KJ; Pagnoux C; McKinnon K; Forbess LJ; Hoffman GS; Borchin R; Krischer JP; Merkel PA;
    Arthritis Rheumatol; 2017 Apr; 69(4):837-845. PubMed ID: 28133925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of biologics in the treatment of giant cell arteritis.
    González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S
    Expert Opin Biol Ther; 2019 Jan; 19(1):65-72. PubMed ID: 30513026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
    Gottenberg JE; Morel J; Perrodeau E; Bardin T; Combe B; Dougados M; Flipo RM; Saraux A; Schaeverbeke T; Sibilia J; Soubrier M; Vittecoq O; Baron G; Constantin A; Ravaud P; Mariette X;
    BMJ; 2019 Jan; 364():l67. PubMed ID: 30679233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of biological agents in the treatment of patients with Takayasu arteritis: a systematic review and meta-analysis.
    Shuai ZQ; Zhang CX; Shuai ZW; Ge SL
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):250-262. PubMed ID: 33506914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of polymyalgia rheumatica and large vessel vasculitis].
    Hellmich B
    Internist (Berl); 2016 Nov; 57(11):1069-1078. PubMed ID: 27631531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
    Huoponen S; Aaltonen KJ; Viikinkoski J; Rutanen J; Relas H; Taimen K; Puolakka K; Nordström D; Blom M
    PLoS One; 2019; 14(7):e0220142. PubMed ID: 31339961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis.
    Schoels M; Aletaha D; Smolen JS; Wong JB
    Ann Rheum Dis; 2012 Aug; 71(8):1303-8. PubMed ID: 22294630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
    Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis.
    Ungprasert P; Thongprayoon C; Davis JM
    Clin Rheumatol; 2016 Jul; 35(7):1795-803. PubMed ID: 26852316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials.
    Amarilyo G; Tarp S; Foeldvari I; Cohen N; Pope TD; Woo JM; Christensen R; Furst DE
    Semin Arthritis Rheum; 2016 Dec; 46(3):312-318. PubMed ID: 27989499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of large-vessel vasculitis.
    Salvarani C; Hatemi G
    Curr Opin Rheumatol; 2019 Jan; 31(1):25-31. PubMed ID: 30461542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.
    Shan J; Zhang J
    Joint Bone Spine; 2019 Mar; 86(2):173-183. PubMed ID: 29635017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect Comparison of Glucocorticoid-Sparing Agents for Remission Maintenance in Giant Cell Arteritis: A Network Meta-analysis.
    Mainbourg S; Tabary A; Cucherat M; Gueyffier F; Lobbes H; Aussedat M; Grenet G; Durieu I; Samson M; Lega JC
    Mayo Clin Proc; 2022 Oct; 97(10):1824-1835. PubMed ID: 35995627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.
    Osman M; Pagnoux C; Dryden DM; Storie D; Yacyshyn E
    PLoS One; 2014; 9(12):e115026. PubMed ID: 25517966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.